

Supplementary Information

Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma

Authors: Yun Jung Choi¹, Dong Ha Kim¹, Dok Hyun Yoon², Cheolwon Suh², Chang-Min Choi^{2,3}, Jae Cheol Lee³, Jung Yong Hong^{3,*}, Jin Kyung Rho^{4,*}

Affiliations:

¹Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, South Korea

²Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, South Korea

³Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, South Korea

⁴Department of Convergence Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, South Korea

*Corresponding authors:

Jung Yong Hong

Department of Oncology, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Tel: +82 2 3205 3208; Fax: +82 2 3010 6961; E-mail: hongjungyong@gmail.com

Jin Kyung Rho

Department of Convergence Medicine, University of Ulsan College of Medicine, 88,

Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Tel: +82 2 3010 2974; Fax: +82 2 3010 6961; E-mail: jkrho@amc.seoul.kr

Supplemental Methods

Cell-free kinase assay

A radioisotopic protein kinase assay (³³PanQinase® Activity Assay, ProQinase GmbH, Freiburg, Germany) was used to measure the kinase activity of protein kinases including a panel of 28 CDK/cyclin complexes formed from 16 CDKs and 15 cyclins.

Supplemental table and figure legends

Table S1. List of targets profiled in Figure 1

Table S2. IC₅₀ values of CDK/cyclin complexes by QS1189

Figure S1. Inhibition of RNAPII CTD phosphorylation by QS1189 treatment

MCL cells were treated with the indicated dose of QS1189 for 24 h. The indicated protein levels were analysed by immunoblotting.


Figure S2. GO analysis of G2/M arrest

RNA sequencing was performed as described in Figure 2. GO analysis of 3-fold upregulated or downregulated genes based on biological processes using DAVID software.


Figure S3. Modulation of anti-apoptotic protein by QS1189 treatment

Cells were treated with the indicated doses of QS1189 for 24 h. The indicated protein levels were analysed by immunoblotting.


Supplemental Figure S1




Supplemental Figure S2



Supplemental Figure S3




Full blots for figure 1c




Full blots for figure 3b and d

3b




3d








Full blots for figure 4b, c and f


4b




4c




4f



Full blots for figure 5b



Full blots for supplemental figure S1



Full blots for supplemental figure S3

